HIGH-DOSE INTRAVENOUS METHYLPREDNISOLONE THERAPY ASSOCIATED WITH OSTEONECROSIS IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS

dc.contributor.authorMASSARDO, L
dc.contributor.authorJACOBELLI, S
dc.contributor.authorLEISSNER, M
dc.contributor.authorGONZALEZ, M
dc.contributor.authorVILLARROEL, L
dc.contributor.authorRIVERO, S
dc.date.accessioned2025-01-23T19:21:58Z
dc.date.available2025-01-23T19:21:58Z
dc.date.issued1992
dc.description.abstractOsteonecrosis is related to the use of steroids in patients with systemic lupus erythematosus (SLE); its association with the use of 'pulses' of methylprednisolone (PMP) is not clear at present. In a retrospective analysis of 190 patients with SLE we found that 19% of 36 patients treated with PMP had osteonecrosis compared with 6% of 154 patients without that treatment (P < 0.04). Risk factors associated with osteonecrosis were PMP treatment, cushingoid appearance, steroid doses greater-than-or-equal-to 40 mg/day during the first month of treatment, a ratio of steroid dose in grams/year greater-than-or-equal-to 12, hematuria and proteinuria. In a stepwise regression model, when cushingoid appearance was excluded, PMP became the only significant factor (P = 0.045).
dc.description.abstractWe conclude that osteonecrosis can be considered a long-term complication of PMP treatment in SLE patients.
dc.fuente.origenWOS
dc.identifier.issn0961-2033
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/98924
dc.identifier.wosidWOS:A1992KF96700010
dc.issue.numero6
dc.language.isoen
dc.pagina.final405
dc.pagina.inicio401
dc.revistaLupus
dc.rightsacceso restringido
dc.subjectOSTEONECROSIS
dc.subjectMETHYLPREDNISOLONE
dc.subjectSYSTEMIC LUPUS ERYTHEMATOSUS
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleHIGH-DOSE INTRAVENOUS METHYLPREDNISOLONE THERAPY ASSOCIATED WITH OSTEONECROSIS IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS
dc.typeartículo
dc.volumen1
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files